Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
|Articles|October 19, 2021
Daily Medication Pearl: Ibrexafungerp (BREXAFEMME) for Vulvovaginal Candidiasis
Author(s)Saro Arakelians, PharmD
Ibrexafungerp is a triterpenoid antifungal drug for adult and post-menarchal pediatric females with vulvovaginal candidiasis.
Advertisement
Medication Pearl of the Day: Ibrexafungerp (BREXAFEMME)
Indication: Ibrexafungerp is a triterpenoid antifungal indicated for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis.
Insight:
- Dosing: The recommended dosage of ibrexafungerp in adult and post-menarchal pediatric females is 300 mg (2 tablets of 150 mg) twice a day for 1 day, for a total treatment dosage of 600 mg.
- Dosage form: Tablets 150 mg.
- Adverse events (AEs): The most frequent AEs associated with this drug are diarrhea, nausea, abdominal pain, dizziness, and vomiting.
- Mechanism of action: Ibrexafungerp is a triterpenoid antifungal drug.
- Manufacturer: Scynexis
Sources:
Advertisement
Related to this article
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
5